The highest quartile of diuretic dosages was considerably higher in the placebo group than in the rolofylline group. Weight loss through the first 4 days was greater by using rolofylline . Extra intravenous vasoactive agents were administered before day 7 in 17 percent of the individuals in the rolofylline group and 16 percent of the sufferers in the placebo group. Primary Efficacy End Factors Rolofylline, as compared with placebo, was not beneficial with respect to the primary end point , yielding an chances ratio of 0.92 . More individuals in the rolofylline group than in the placebo group fulfilled the criteria for treatment success .More info on the clinical research is available at Zinthionein is Adeona’s one dose, proprietary, gastro-retentive, sustained-launch, oral formulation of zinc cysteine that’s intended to have better bioavailability of zinc compared to the FDA-approved planning of inorganic zinc acetate. In addition, Zinthionein is made to be better tolerated with considerably less gastrointestinal side results than the FDA-approved preparation of inorganic zinc acetate. Adeona expects that Component 2 of the CopperProof-2 study should be completed by the finish of March 2011. If effective, Adeona would be prepared to make commercially obtainable its Zinthionein product as a prescription medical meals for Alzheimer’s disease and gentle cognitive impairment individuals.